Published in AIDS Weekly, January 8th, 2001
Funding from this grant will be used to advance PTC's RNA-based approach for developing novel HIV drugs that target the mechanism the virus uses to replicate. The company's unique approach is based on interfering with an essential protein production process - called "programmed ribosomal frameshifting" - required by the virus for its survival.
The usual process of producing proteins is highly accurate and ensures that individual mRNAs will almost always lead to very...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.